What is the recommended management for an adult with active inflammatory ileocolitis?

Management of Active Inflammatory Ileocolitis in Adults

For mild ileocolonic Crohn's disease, initiate high-dose mesalazine 4 g daily as first-line therapy; for moderate to severe disease or mesalazine failure, use prednisolone 40 mg daily, tapered gradually over 8 weeks. 1

Disease Assessment Framework

Before initiating treatment, assess three critical parameters that determine therapeutic approach 1:

• Site: Confirm ileal, ileocolic involvement through imaging/endoscopy
• Pattern: Distinguish inflammatory vs. stricturing vs. fistulating disease
• Activity: Grade severity as mild, moderate, or severe based on clinical indices

Critical pitfall: Always exclude alternative explanations for symptoms including bacterial overgrowth, bile salt malabsorption, fibrotic strictures, and infectious complications (particularly Clostridioides difficile and cytomegalovirus) before escalating therapy 1, 2.

Treatment Algorithm by Disease Severity

Mild Ileocolonic Disease

• First-line: Mesalazine 4 g daily (grade A evidence) 1
• This achieves partial or complete remission in approximately 60% of patients with mild to moderate disease 3
• Continue for adequate trial period before declaring treatment failure 4

Moderate to Severe Disease or Mesalazine Failure

• Oral corticosteroids: Prednisolone 40 mg daily (grade A evidence) 1
• Taper schedule: Reduce gradually over 8 weeks according to clinical response; more rapid reduction increases early relapse risk 1
• Alternative for isolated ileo-caecal disease: Budesonide 9 mg daily is appropriate but marginally less effective than prednisolone (grade A evidence) 1. Budesonide offers reduced systemic side effects with comparable efficacy in this specific location 5, 6

Severe Disease Requiring Hospitalization

• Intravenous steroids: Hydrocortisone 400 mg/day or methylprednisolone 60 mg/day (grade B evidence) 1
• Concomitant antibiotics: Add intravenous metronidazole as it may be difficult to distinguish active disease from septic complications 1
• Supportive measures: 1
  • IV fluid and electrolyte replacement
  • Subcutaneous heparin for thromboembolism prophylaxis (grade B)
  • Nutritional support if malnourished (grade C)
  • Blood transfusion to maintain hemoglobin >10 g/dL

Adjunctive and Steroid-Sparing Therapies

Immunomodulators

• Azathioprine 1.5-2.5 mg/kg/day or mercaptopurine 0.75-1.5 mg/kg/day: Use as adjunctive therapy and steroid-sparing agents (grade A evidence) 1
• Critical limitation: Slow onset of action precludes use as sole therapy for active disease 1
• Requires regular hematological monitoring during long-term use 6

Nutritional Therapy

• Elemental or polymeric diets: Less effective than corticosteroids but appropriate for patients with contraindications to steroids or those preferring to avoid them (grade A evidence) 1
• Can serve as adjunctive therapy (grade C evidence) 1

Biological Therapy

• Infliximab 5 mg/kg: Effective for active disease (grade A evidence) but best avoided in patients with obstructive symptoms 1
• Should be reserved for steroid-refractory disease or as part of accelerated step-up approach in appropriate patients 4

Surgical Considerations

Surgery should be considered for medical therapy failure and may be appropriate as primary therapy in patients with limited ileal or ileo-caecal disease (grade C evidence) 1. This represents an important option that should not be delayed inappropriately, as timely surgery can improve quality of life in selected patients 4.

Common Pitfalls to Avoid

• Overprescription of mesalamine: While effective for mild disease, do not persist with mesalamine monotherapy in moderate-severe disease or after clear treatment failure 4
• Inappropriate steroid use: Never use steroids for maintenance therapy; they are for induction only 4, 6
• Delayed immunomodulator introduction: Do not wait too long to add azathioprine/mercaptopurine in steroid-dependent patients 4
• Failure to exclude infection: Always test for C. difficile and consider CMV before escalating immunosuppression 2

Patient Engagement

Patients should actively participate in treatment decisions regarding aminosalicylates, corticosteroids, nutritional therapy, biologics, or surgery, with treatment tailored to disease severity and patient preferences 1.